SCHEMBL2247342

SCHEMBL2247342

CC(C)(Cc1ccc(F)cc1)N[C@@H](CCC(N)=O)C(=O)OC(=O)c1ccc(-c2ccc(Cl)s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.41
MMP8 P22894 2/20 0.41
MMP12 P39900 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
KLKB1 P03952 4/20 0.37
KDM1A O60341 1/20 0.35
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CASR P41180 3/20 0.33
IKBKB O14920 1/20 0.33
ADRB2 P07550 2/20 0.32
ADRB1 P08588 2/20 0.32
ADRB3 P13945 2/20 0.32
PRSS1 P07477 1/20 0.32
TMPRSS15 P98073 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2253122 1.00 MMP2 (0.41) MMP2MMP8MMP12ADAMTS5KLKB1
SCHEMBL2245793 0.92 MMP2 (0.41) MMP2MMP8MMP12ADAMTS5KDM1A
SCHEMBL2249892 0.89 MMP2 (0.49) MMP2MMP8MMP12ADAMTS5KDM4E
SCHEMBL2242489 0.89 MMP2 (0.46) MMP2MMP8MMP12ADAMTS5MAPT
SCHEMBL2251614 0.89 HPGDS (0.42) MMP2MMP8MMP12ADAMTS5CASR
SCHEMBL2246078 0.87 IKBKB (0.40) MMP2MMP8MMP12ADAMTS5KDM4E
SCHEMBL2247684 0.86 MMP2 (0.45) MMP2MMP8MMP12ADAMTS5CASR
SCHEMBL2249695 0.86 FNTA (0.35) MMP2MMP8MMP12ADAMTS5KLKB1
SCHEMBL2245736 0.85 HPGDS (0.36) MMP2MMP8MMP12ADAMTS5KLKB1
SCHEMBL2254236 0.85 MMP2 (0.47) MMP2MMP8MMP12ADAMTS5ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP2 49/4885MMP8 70/4885MMP12 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.